Search Results

Biotech Bay

Attralus, Inc., a clinical-stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced that it has closed a $56 million financing.

February 6, 2024

·

7 min read

Biotech Bay

Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at the XIX International Symposium on Amyloidosis (ISA)

Attralus, Inc. announced 11 data presentations, including two oral presentations related to the use of 124I-evuzamitide, the company’s pan-amyloid binding imaging agent in development for the diagnosis of cardiac amyloidosis.

May 30, 2024

·

12 min read

Biotech Bay

Attralus Announces Publication of Two Studies Evaluating Iodine (124I) Evuzamitide (AT-01) using PET/CT in the Journal of American College of Cardiology (JACC CV Imaging)

Attralus, Inc. announced the publication of results from two Attralus-funded investigator-initiated studies of 124I-evuzamitide, the company’s investigational pan-amyloid radiotracer under development for the diagnosis and management of systemic amyloidosis.

November 7, 2023

·

10 min read

Press Releases

Attralus Receives Breakthrough Therapy Designation for its Pan-Amyloid Diagnostic PET Imaging Candidate 124I-evuzamitide (AT-01) for Cardiac Amyloidosis

August 5, 2024

·

4 min read

Press Releases

Attralus Receives European Medicines Agency Committee for Orphan Medicinal Products (COMP) Positive Opinions for AT-02 for the Treatment of Both ATTR and AL Amyloidosis

July 29, 2024

·

5 min read

Biotech Bay

Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at the 28th Annual Scientific Session of the American Society of Nuclear Cardiology

Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced eight data presentations (from an Attralus sponsored trial and from four investigator-initiated trials) related to the use of 124I-evuzamitide (AT-01), the company’s pan-amyloid binding imaging agent in development for the diagnosis and management of all types of systemic amyloidosis.

October 2, 2023

·

12 min read

Biotech Bay

Attralus to Present New Data on Its Amyloidosis Portfolio at the 2022 International Symposium on Amyloidosis

Attralus, Inc. today announced that new data across the Company’s amyloidosis portfolio will be presented in both oral and poster presentations at the XVIII International Symposium on Amyloidosis (ISA) by Attralus, the University of Tennessee Graduate School of Medicine and the Brigham and Women’s Hospital.

August 22, 2022

·

8 min read

Drug Development

Attralus Announces First Subject Enrolled in Phase 1 Clinical Trial of AT-02, Its Lead Pan-Amyloid Removal Therapeutic Candidate

Attralus, Inc. today announced that the first subject has been dosed in the Phase 1 clinical trial of AT-02, the company’s lead pan-amyloid removal (PAR) therapeutic.

October 17, 2022

·

4 min read

Business

Attralus Appoints James Testa as Vice President of Finance

Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced the appointment of James Testa as Vice President of Finance.

February 10, 2022

·

2 min read

Business

Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders

Attralus, Inc. and Ossianix announced today that they have entered into a definitive agreement using Ossianix’ brain shuttle technology to enhance the targeted delivery of novel pan-amyloid removal candidates for use in neurodegenerative disorders such as Alzheimer’s Disease.

November 17, 2022

·

4 min read